• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fatal heart tamponade during induction treatment with azacitidine and venetoclax.

作者信息

Krecak Ivan, Supe Marijana, Markov Bernarda, Skelin Marko, Lucijanic Marko

机构信息

Department of Internal Medicine, General Hospital of Sibenik-Knin County, Sibenik, Croatia.

Faculty of Medicine, University of Rijeka, Rijeka, Croatia.

出版信息

Ann Hematol. 2024 Nov;103(11):4827-4829. doi: 10.1007/s00277-024-05957-9. Epub 2024 Aug 25.

DOI:10.1007/s00277-024-05957-9
PMID:39182200
Abstract
摘要

相似文献

1
Fatal heart tamponade during induction treatment with azacitidine and venetoclax.阿扎胞苷和维奈克拉诱导治疗期间发生致命性心脏压塞。
Ann Hematol. 2024 Nov;103(11):4827-4829. doi: 10.1007/s00277-024-05957-9. Epub 2024 Aug 25.
2
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.新诊断为不符合强化诱导化疗条件的急性髓系白血病患者中，基于 venetoclax 的联合治疗使每位患者达到缓解的成本。
J Manag Care Spec Pharm. 2022 Sep;28(9):980-988. doi: 10.18553/jmcp.2022.22021. Epub 2022 Jun 16.
3
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.伴有阿扎胞苷的维奈托克治疗未经治疗的急性髓系白血病患者的真实世界经验。
Blood Adv. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243.
4
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
5
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
6
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.新诊断的急性髓系白血病中基于微小残留病灶指导的阿扎胞苷停药的高剂量维奈托克。
Haematologica. 2023 Oct 1;108(10):2616-2625. doi: 10.3324/haematol.2023.282681.
7
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.强化或低强度诱导后急性髓系白血病患者采用小剂量阿扎胞苷联合维奈托克作为维持治疗的单中心、单臂、2 期临床试验。
Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6.
8
Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.抗体药物偶联物 ASP1235 靶向 Fms 样酪氨酸激酶 3 联合维奈克拉和阿扎胞苷在急性髓系白血病异种移植小鼠模型中的抗肿瘤作用。
Oncotarget. 2022 Dec 20;13:1359-1368. doi: 10.18632/oncotarget.28331.
9
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.初治 AML 患者采用维奈托克联合阿扎胞苷治疗的遗传风险分层和结局。
Blood. 2024 Nov 21;144(21):2211-2222. doi: 10.1182/blood.2024024944.
10
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.阿扎胞苷和维奈托克治疗不适合治疗的初治急性髓系白血病患者的成本效益。
Blood Adv. 2021 Feb 23;5(4):994-1002. doi: 10.1182/bloodadvances.2020003902.

本文引用的文献

1
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.新诊断的急性髓系白血病患者在接受 venetoclax+低甲基化药物治疗期间的心脏事件。
Br J Haematol. 2024 Apr;204(4):1232-1237. doi: 10.1111/bjh.19325. Epub 2024 Feb 4.
2
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.报告的与急性髓细胞性白血病治疗相关的心包毒性：FDA 不良报告数据库的药物警戒分析。
Curr Probl Cardiol. 2022 Nov;47(11):101345. doi: 10.1016/j.cpcardiol.2022.101345. Epub 2022 Aug 7.
3
Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF-κB and BCL-2 Pathway.
维奈托克通过 NF-κB 和 BCL-2 通路调节氧化应激介导的心脏炎症和细胞凋亡诱导心脏毒性。
Int J Mol Sci. 2022 Jun 2;23(11):6260. doi: 10.3390/ijms23116260.
4
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents.接受维奈克拉联合去甲基化药物治疗的急性髓系白血病患者的心脏事件
Blood Adv. 2022 Sep 13;6(17):5227-5231. doi: 10.1182/bloodadvances.2022007333.
5
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.伴有 venetoclax 和唑类抗真菌药物的急性髓系白血病患者的细胞减少持续时间。
Cancer. 2021 Jul 15;127(14):2489-2499. doi: 10.1002/cncr.33508. Epub 2021 Apr 1.
6
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
7
Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?慢性粒单核细胞白血病中的心血管疾病：单核细胞增多症和慢性炎症是否会导致动脉粥样硬化加速？
Ann Hematol. 2019 Jan;98(1):101-109. doi: 10.1007/s00277-018-3489-0. Epub 2018 Sep 4.
8
Pericardial tamponade in chronic myelomonocytic leukemia.慢性粒单核细胞白血病并发心包填塞
Chest. 1994 Sep;106(3):967-70. doi: 10.1378/chest.106.3.967.